Biotest Valuation

Is BIO3 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BIO3 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BIO3 (€27.1) is trading below our estimate of fair value (€92.66)

Significantly Below Fair Value: BIO3 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BIO3?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for BIO3. This is calculated by dividing BIO3's market cap by their current preferred multiple.
What is BIO3's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	€1.36b

BIO3 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.5x
Enterprise Value/EBITDA	9.3x
PEG Ratio	-0.1x

Price to Earnings Ratio vs Peers

How does BIO3's PE Ratio compare to its peers?

The above table shows the PE ratio for BIO3 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	19.4x
FYB Formycon	13.8x	30.5%	€882.8m
2INV 2invest	12x	n/a	€60.4m
DMP Dermapharm Holding	21x	18.5%	€1.7b
GXI Gerresheimer	30.8x	22.3%	€3.5b
BIO3 Biotest	6.5x	-67.2%	€1.4b

Price-To-Earnings vs Peers: BIO3 is good value based on its Price-To-Earnings Ratio (6.5x) compared to the peer average (19.4x).

Price to Earnings Ratio vs Industry

How does BIO3's PE Ratio compare vs other companies in the European Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	35.8%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	35.8%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: BIO3 is good value based on its Price-To-Earnings Ratio (6.5x) compared to the European Biotechs industry average (26.4x).

Price to Earnings Ratio vs Fair Ratio

What is BIO3's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BIO3 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	6.5x
Fair PE Ratio	3.9x

Price-To-Earnings vs Fair Ratio: BIO3 is expensive based on its Price-To-Earnings Ratio (6.5x) compared to the estimated Fair Price-To-Earnings Ratio (3.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.